CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Uncover wealth-building strategies for the future. Take actionable steps today to secure your financial well-being.
20,267 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
The u.s. strategic petroleum reserve is approaching panic levels as stockpiles shrink, forcing traders to reassess en...
Global inflation roars back globally as energy markets tighten amid geopolitical tensions, threatening budgets and co...
A couple aged 66 with $2.2M discovers hidden spending during a retirement audit, challenging their withdrawal strateg...
XRPL posted the strongest 90-day RWAs inflow among major blockchains, narrowly topping Ethereum and Solana. Analysts ...
Strategy faces a critical test as STRC falls below $90, despite new claims of decades-long dividend coverage backed b...
Illinois has floated a plan to fix its long-broken alcohol tax system. This article explains what the proposal actual...
Strategy, formerly MicroStrategy, used $300 million to shore up liquidity while continuing to fund Bitcoin purchases....
SpaceX (SPCX) has fallen about 30% from its peak while planning a large debt raise. This guide breaks down what the d...
A new poll in 2026 finds a rising minority of Gen Z workers would prefer a robot supervisor, challenging traditional ...
A Florida grocery worker allegedly exploited lottery access to scan scratch-offs, netting tens of thousands in winnin...
A little-known small-cap ETF is turning heads with bold gains in 2026. This guide explains what’s driving the perform...